GRAI-MATTER-LABS
4.10.2021 13:04:09 CEST | Business Wire | Press release
GrAI Matter Labs (GML), a pioneer of brain-inspired ultra-low latency computing solutions, and FRAMOS, a leading global imaging provider, will unite at VISION 2021 to create Life-Ready AI for Industrial Vision Platforms. This project is based on FRAMOS’s D435e Industrial Depth Camera and GML's GrAI VIP (Vision Inference Processor) and was formed to advance vision application development in robotics, automation, IoT-connected manufacturing, and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005462/en/
The Life-Ready AI for Industrial Vision Platforms will be built on GML's pioneering development of brain-inspired computing techniques for enhanced efficiencies that leverages FRAMOS’s state of the art stereo depth sensing technology for industrial environments through their D435e stereo depth camera. The platform offers full bodied IP66 rated cameras, or board level modules for easy and flexible integration into industrial designs, both with M12 ethernet and M8 power connectors, and are enabled with ultra low latency AI processing for applications such as orientation and tracking for robots; navigation of autonomous transport systems (AGVs); among some of the many possibilities.
GML and FRAMOS will showcase the integration of the Life-Ready AI platform and D435e Industrial Depth Camera at the Vision 2021 in Stuttgart, Germany, taking place over three days starting October 5th .
“We are proud to be working with FRAMOS to couple GML's "Life-Ready AI" chips, state-of-the-art brain-inspired computing architecture, and FRAMOS' robust D400e depth camera series, to enable many types of new low latency applications in industrial manufacturing that will allow us to bring AI processing closer to where data is generated. This collaboration enables us to realize the full potential of end-point AI, allowing for actionable insights into manufacturing operations to improve productivity and lower costs,” said Christian Verbrugge, GML Europe - Senior Director Business Development.
Ferdinand Reitze, FRAMOS Product Manager 3D, is delighted about the integration, saying: “GML successfully reduced the footprint of AI inference at the edge, while achieving best results, speed and low latency. Together with our D400e series, the Life-Ready AI chips will enable new ways to resolve todays and tomorrows challenges in robotics and automation for our customers.”
About GrAI Matter Labs
At GrAI Matter Labs we are in the business of Life-Ready AI. Artificial Intelligence as close to natural as it gets. AI that feels alive. We deliver brain-inspired chips that behave like humans. AI that makes machines act and react in real-time. AI that optimizes energy and maximizes efficiency, saving time, money, and vital natural resources. GML is led by a team of visionary and seasoned engineers and is backed by leading investors, including iBionext, 360 Capital Partners, 3T Finance, and Celeste Management.
For more information, please visit www.graimatterlabs.ai .
About FRAMOS
FRAMOS® is an imaging expert, trusted advisor, and vision solutions provider. Since 1981 FRAMOS implements the best current and emerging imaging technologies for specific customer requirements and applications. FRAMOS meets these requirements with advanced and proven imaging components from a global network of renowned partners, and proprietary IP.
More than 170 FRAMOS employees world-wide are passionate about the unlimited potential of imaging and help customers achieve the optimum results from every possible scenario. FRAMOS drives and ensures the entire product development journey. This journey starts with the careful selection of imaging components, like image sensors, lenses, through various 3D technologies, to custom development tailored to individual needs and time frames. FRAMOS listens and understands customer challenges. With innovative solutions FRAMOS ensures successful project outcomes and develops long-term customer relations.
For more information, please visit www.framos.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005462/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Expands ConnectAI Charter Program with Mars Snacking22.10.2026 12:45:00 CEST | Press release
Mars joins a growing group of global companies working with NIQ forward-deployed engineers to bring proprietary consumer and market intelligence into enterprise AI workflows NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced Mars as a new ConnectAI Charter client, expanding the program’s growing roster of global companies working with NIQ to build the intelligence foundation for amplifying enterprise AI workflows. Through the ConnectAI Charter Program, NIQ forward-deployed engineers and data scientists are working with Mars to embed NIQ intelligence in the expansion of AI-enabled workflows across its business. The engagement focuses on connecting NIQ data, models, and business context with Mars’ AI ecosystem to help reduce the distance between data and decision-making. Together, they are tackling use cases like conversational analytics and harmonized product data to lay the foundation for future use cases. “As we expand the use of AI across our business, we
Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer22.10.2026 12:18:00 CEST | Press release
An independent, blinded evaluation of 620 patients from the phase III PANTHER trial identified nearly one-quarter as Low Risk despite clinically high-risk breast cancer, with favorable ten-year outcomes. Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden. Independent, Blinded Evaluation Using Phase III Trial Data The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dxpredictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified p
Zoomtopia: Zoom lancerer nye AI-funktioner22.10.2026 12:13:00 CEST | Pressemeddelelse
Zoom vil forkorte vejen fra mødebeslutning til udført arbejde. På konferencen Zoomtopia præsenterer virksomheden Unified Context Layer – et fælles informationslag, der forbinder samtaler, dokumenter og data, så AI kan forstå sammenhængen og hjælpe med de næste skridt. Samtidig lanceres flere nye AI-produkter og -funktioner, der skal gøre det lettere at omsætte diskussioner og beslutninger til handling. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261021318859/da/ I møder og samtaler træffes vigtige beslutninger, og virksomheder får værdifuld indsigt i deres kunder. En kundedialog kan begynde i et møde, fortsætte i telefonen og derefter gå over i en chat. Når informationen spredes mellem forskellige værktøjer, bliver det svært for både medarbejdere og AI-agenter at få et samlet billede af, hvad der er blevet sagt og besluttet. Resultatet er, at værdifuld tid går med at finde ud af, hvad der er blevet sagt og besluttet, og
TACTICAAI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 12:01:00 CEST | Press release
Collaboration brings together TACTICAAI’s operational decision-intelligence technology and NVIDIA AI capabilities to advance reasoning, autonomous analysis and video intelligence for real-world deployment TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
